EGFR and non-small cell lung carcinoma: Regarding the effectiveness of gefitinib within NSCLC patients having an epidermal growth factor receptor (EGFR) mutated status, gefitinib was found to have elevated efficacy levels in salvage and within NSCLC patients carrying the exon 19 deletion mutation and/or exon 21 Leu858Arg mutation status.